CNS Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
CNS Pharmaceuticals, Inc. (CNSP) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$34.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-12
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was -$611.79K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was $577.79K, a 54.99% increase year-over-year.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $1.81M.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $667.59K.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $1.54M.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$3.63M, a 374.91% decline from fiscal 2023.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $1.32M, a 42.62% decline from fiscal 2022.
- CNS Pharmaceuticals, Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $2.30M.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$611.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$34.00K 10-Q · filed 2026-08-12 | $1.78M derived: sum of 3 quarters · filed 2026-08-12 | $2.44M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2026-03-31 | $577.79K 10-Q · filed 2026-05-14 | $2.39M derived: sum of 2 quarters · filed 2026-05-14 | $3.06M derived: sum of 3 quarters · filed 2026-05-14 | $1.75M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $2.48M derived: sum of 2 quarters · filed 2026-03-31 | $1.17M derived: sum of 3 quarters · filed 2026-08-12 | $1.54M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $667.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$640.20K derived: sum of 2 quarters · filed 2026-08-12 | -$267.41K 10-Q · filed 2025-11-14 | -$2.09M derived: sum of 4 quarters · filed 2026-08-12 | |
| 2025-06-30 | -$1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$935.00K 10-Q · filed 2026-08-12 | -$934.61K 10-Q · filed 2025-08-14 | -$2.76M derived: sum of 3 quarters · filed 2026-08-12 | -$5.38M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $372.78K 10-Q · filed 2026-05-14 | -$1.45M derived: sum of 2 quarters · filed 2026-05-14 | -$4.07M derived: sum of 3 quarters · filed 2026-05-14 | -$3.31M derived: sum of 4 quarters · filed 2026-05-14 | |
| 2024-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$4.44M derived: sum of 2 quarters · filed 2026-03-31 | -$3.68M derived: sum of 3 quarters · filed 2026-03-31 | -$3.63M 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.85M derived: sum of 2 quarters · filed 2025-11-14 | -$1.81M 10-Q · filed 2025-11-14 | -$1.15K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $761.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $807.46K 10-Q · filed 2025-08-14 | $2.61M derived: sum of 3 quarters · filed 2025-08-14 | $2.81M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $46.14K 10-Q · filed 2025-05-15 | $1.85M derived: sum of 2 quarters · filed 2025-05-15 | $2.05M derived: sum of 3 quarters · filed 2025-05-15 | $2.24M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.00M derived: sum of 2 quarters · filed 2025-03-31 | $2.20M derived: sum of 3 quarters · filed 2025-03-31 | $1.32M 10-K · filed 2025-03-31 | |
| 2023-09-30 | $196.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $393.06K derived: sum of 2 quarters · filed 2024-11-14 | -$483.40K 10-Q · filed 2024-11-14 | $2.00M derived: sum of 4 quarters · filed 2024-11-14 | |
| 2023-06-30 | $196.94K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$679.52K 10-Q · filed 2024-08-14 | $1.80M derived: sum of 3 quarters · filed 2024-08-14 | ||
| 2023-03-31 | -$876.46K 10-Q · filed 2024-05-15 | $1.60M derived: sum of 2 quarters · filed 2024-05-15 | |||
| 2022-12-31 | $2.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.30M 10-K · filed 2024-04-01 | |||
| 2022-09-30 | -$175.29K 10-Q · filed 2023-11-14 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$50.00K derived: sum of 2 quarters · filed 2020-11-12 | -$45.83K 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | -$50.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$45.83K 10-Q · filed 2020-08-10 | |||
| 2020-03-31 | $4.17K 10-Q · filed 2020-05-15 | ||||
| 2019-09-30 | $10.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $10.00K derived: sum of 2 quarters · filed 2020-11-12 | $9.21K 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$794.00 10-Q · filed 2020-08-10 | |||
| 2019-03-31 | -$794.00 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |